134 related articles for article (PubMed ID: 21385271)
21. The sFas/sFasL ratio as a novel marker of inflammation in children with chronic kidney disease.
Musiał K; Zwolińska D
Clin Chim Acta; 2012 Dec; 414():7-11. PubMed ID: 22898262
[TBL] [Abstract][Full Text] [Related]
22. Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF.
Onalan G; Selam B; Baran Y; Cincik M; Onalan R; Gündüz U; Ural AU; Pabuccu R
Hum Reprod; 2005 Sep; 20(9):2391-5. PubMed ID: 15932917
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
[TBL] [Abstract][Full Text] [Related]
24. Serum soluble fas level as a prognostic factor in patients with gynecological malignancies.
Konno R; Takano T; Sato S; Yajima A
Clin Cancer Res; 2000 Sep; 6(9):3576-80. PubMed ID: 10999747
[TBL] [Abstract][Full Text] [Related]
25. Serum sFas/sFasL ratio in systemic lupus erythematosus (SLE) is a function of age.
Turi MC; D'Urbano M; Celletti E; Alessandri C; Valesini G; Paganelli R
Arch Gerontol Geriatr; 2009; 49 Suppl 1():221-6. PubMed ID: 19836636
[TBL] [Abstract][Full Text] [Related]
26. Elevated serum soluble Fas ligand is a promising marker of testicular toxicity induced by epirubicin in rats.
Geng J; Fan J; Jiang HW; Fang ZJ; Wang X; Sun JL; Ding Q; Chen G
Toxicol Lett; 2009 Apr; 186(2):96-103. PubMed ID: 19429229
[TBL] [Abstract][Full Text] [Related]
27. Apoptosis markers soluble Fas (sFas), Fas Ligand (FasL) and sFas/FasL ratio in patients with bacteremia: a prospective cohort study.
Huttunen R; Syrjänen J; Vuento R; Laine J; Hurme M; Aittoniemi J
J Infect; 2012 Mar; 64(3):276-81. PubMed ID: 22207003
[TBL] [Abstract][Full Text] [Related]
28. Soluble Fas and soluble Fas L levels in patients with acute pancreatitis.
Endo S; Inoue Y; Fujino Y; Yamada Y; Sato N; Wakabayashi G; Sakamoto T; Ishikura H; Tanaka T; Inada K; Sato S
Res Commun Mol Pathol Pharmacol; 2000; 108(3-4):179-86. PubMed ID: 11913710
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer.
Mizutani Y; Yoshida O; Ukimura O; Kawauchi A; Bonavida B; Miki T
Cancer Biother Radiopharm; 2002 Oct; 17(5):563-7. PubMed ID: 12470426
[TBL] [Abstract][Full Text] [Related]
30. Upregulation of the sFas/sFasL system in psoriatic patients.
Myśliwiec H; Baran A; Myśliwiec P; Górska M; Flisiak I
Adv Med Sci; 2015 Mar; 60(1):64-8. PubMed ID: 25437350
[TBL] [Abstract][Full Text] [Related]
31. Levels of HBV-DNA, sFas and sFasL among healthy HBsAg carriers in period of three years.
Lapiński TW; Kovalczuk O; Flisiak R; Pancewicz J
Adv Med Sci; 2006; 51():46-50. PubMed ID: 17357276
[TBL] [Abstract][Full Text] [Related]
32. High soluble Fas and soluble Fas Ligand serum levels before stent implantation are protective against restenosis.
Katsaros KM; Wiesbauer F; Speidl WS; Kastl SP; Huber K; Zorn G; Niessner A; Glogar D; Maurer G; Wojta J
Thromb Haemost; 2011 May; 105(5):883-91. PubMed ID: 21359408
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the maternal and umbilical vein serum sFas/sFasL system in pregnancies complicated by preeclampsia with intrauterine growth retardation.
Laskowska M; Laskowska K; Leszczyńska-Gorzelak B; Oleszczuk J
Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):155-9. PubMed ID: 16169656
[TBL] [Abstract][Full Text] [Related]
34. Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease.
Takabatake N; Nakamura H; Inoue S; Terashita K; Yuki H; Kato S; Yasumura S; Tomoike H
Respir Med; 2000 Dec; 94(12):1215-20. PubMed ID: 11192958
[TBL] [Abstract][Full Text] [Related]
35. Human chorionic gonadotropin and free subunits' serum levels in patients with partial and complete hydatidiform moles.
Berkowitz R; Ozturk M; Goldstein D; Bernstein M; Hill L; Wands JR
Obstet Gynecol; 1989 Aug; 74(2):212-6. PubMed ID: 2473429
[TBL] [Abstract][Full Text] [Related]
36. Soluble Fas, Fas ligand and Bcl-2 in autoimmune thyroid diseases: relation to humoral immune response markers.
Myśliwiec J; Okota M; Nikołajuk A; Górska M
Adv Med Sci; 2006; 51():119-22. PubMed ID: 17357290
[TBL] [Abstract][Full Text] [Related]
37. Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment.
Pignataro L; Arisi E; Sambataro G; Corsi MM
J Surg Oncol; 2003 Jun; 83(2):112-5. PubMed ID: 12772205
[TBL] [Abstract][Full Text] [Related]
38. Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands.
Kerkmeijer LG; Wielsma S; Massuger LF; Sweep FC; Thomas CM
Gynecol Oncol; 2007 Jul; 106(1):142-6. PubMed ID: 17462723
[TBL] [Abstract][Full Text] [Related]
39. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients.
Ugurel S; Rappl G; Tilgen W; Reinhold U
Clin Cancer Res; 2001 May; 7(5):1282-6. PubMed ID: 11350895
[TBL] [Abstract][Full Text] [Related]
40. Comparison of human chorionic gonadotropin +beta and invasive trophoblast antigen disappearance rates in serum after evacuation of molar pregnancy.
Van Trommel NE; Sweep FC; Ross HA; Massuger LF; Thomas CM
Int J Mol Med; 2006 Oct; 18(4):705-11. PubMed ID: 16964426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]